Bruton's tyrosine kinase: oncotarget in myeloma

被引：0
|
作者：
Tai, Yu-Tzu [1 ,2 ]
Anderson, Kenneth C. [1 ,2 ]
机构：
[1] Harvard Univ, Sch Med, LeBow Inst Myeloma Therapeut, Boston, MA 02114 USA
[2] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA
来源：
ONCOTARGET | 2012年 / 3卷 / 09期
关键词：
BTK; INHIBITION; CELLS;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：913 / 914
页数：2
相关论文
共 50 条
  • [41] Bruton's tyrosine kinase (Btk) associates with protein kinase C μ
    Johannes, FJ
    Hausser, A
    Storz, P
    Truckenmüller, L
    Link, G
    Kawakami, T
    Pfizenmaier, K
    FEBS LETTERS, 1999, 461 (1-2) : 68 - 72
  • [42] Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase
    Pan, Zhengying
    Scheerens, Heleen
    Li, Shyr-Jiann
    Schultz, Brian E.
    Sprengeler, Paul A.
    Burrill, L. Chuck
    Mendonca, Rohan V.
    Sweeney, Michael D.
    Scott, Keana C. K.
    Grothaus, Paul G.
    Jeffery, Douglas A.
    Spoerke, Jill M.
    Honigberg, Lee A.
    Young, Peter R.
    Dalrymple, Stacie A.
    Palmer, James T.
    CHEMMEDCHEM, 2007, 2 (01) : 58 - 61
  • [43] Mutations in Bruton's Tyrosine Kinase Impair IgA Responses
    Mitsuiki, N.
    Yang, X.
    Bartol, S.
    Kosaka, Y.
    Takada, H.
    Imai, K.
    Kanegane, H.
    Mizutani, S.
    van der Burg, M.
    van Zelm, M.
    Ohara, O.
    Morio, T.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 : S430 - S431
  • [44] The Use of Bruton Tyrosine Kinase Inhibitors in Waldenstrom's Macroglobulinemia
    Khan, Abdullah Mohammad
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (05):
  • [45] Targeted selective degradation of Bruton's tyrosine kinase by PROTACs
    Liu, Shaodong
    Da, Yang
    Wang, Feng
    Yan, Renjie
    Shu, Yongzhi
    Lin, Pei
    Lin, Jun
    MEDICINAL CHEMISTRY RESEARCH, 2020, 29 (04) : 802 - 808
  • [46] PRECLINICAL ACTIVITY OF NOVEL BRUTON'S TYROSINE KINASE INHIBITOR ARQ531 ON MULTIPLE MYELOMA CELLS
    Retali, V.
    Soncini, D.
    Minetto, P.
    Ruberti, S.
    Contini, P.
    Rivoli, G.
    Bisso, N.
    Di Felice, N.
    Cagnetta, A.
    Eathiraj, S.
    Abbadessa, G.
    Schwartz, B.
    Gobbi, M.
    Lemoli, R. M.
    Cea, M.
    HAEMATOLOGICA, 2018, 103 : S114 - S114
  • [47] Novel Disubstituted Pyrimidines as Inhibitors of Bruton's Tyrosine Kinase
    Rosse, Gerard
    ACS MEDICINAL CHEMISTRY LETTERS, 2015, 6 (01): : 23 - 24
  • [48] Targeting Bruton's tyrosine kinase in B cell malignancies
    Rudi W. Hendriks
    Saravanan Yuvaraj
    Laurens P. Kil
    Nature Reviews Cancer, 2014, 14 : 219 - 232
  • [49] A review of Bruton's tyrosine kinase inhibitors in multiple sclerosis
    Airas, Laura
    Bermel, Robert A.
    Chitnis, Tanuja
    Hartung, Hans-Peter
    Nakahara, Jin
    Stuve, Olaf
    Williams, Mitzi J.
    Kieseier, Bernd C.
    Wiendl, Heinz
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2024, 17
  • [50] Bruton's tyrosine kinase inhibitors in the treatment of multiple sclerosis
    Shulga, Olga
    Chabanova, Anna
    Kotsiuba, Oleksandra
    POSTEPY PSYCHIATRII I NEUROLOGII, 2023, 32 (01): : 23 - 30
12345